Importantly, NGS was not conducted on all PETALS participants (although it was conducted even if tumour tests did not demonstrate MMR deficiency in young patients and those with suggestive family histories), and it was possible that a direct NGS strategy may have identified additional pathogenic MMR variants. This evidence concerns the gene MRC1 and neoplasm.